This Article Full Text Full Text (PDF) All Versions of this Article: 30/6/726    most recent Author Manuscript (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heufelder, A. E. Articles by Gooren, L. Search for Related Content PubMed PubMed Citation Articles by Heufelder, A. E. Articles by Gooren, L.

Fifty-two–Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone

FARID SAAD^,

MATHIJS C. BUNCK

LOUIS GOOREN

From Business Unit Primary Care, Men's Healthcare, Scientific Affairs, Bayer Schering Pharma AG, Berlin, Germany; Gulf Medical University, Ajman, United Arab Emirates; and the Department of Endocrinology, Vrije University Medical Center, Amsterdam, the Netherlands. ^* Dr Heufelder is in private practice in Munich, Germany.

Correspondence to: Dr Louis Gooren, Department of Endocrinology, VU University Medical Center, De Boelelaan 1117, 10881 HV Amsterdam, the Netherlands (e-mail: louisjgooren{at}gmail.com).

Abstract

Men with the metabolic syndrome (MetS) and type 2 diabetes (T2D) often have low testosterone levels. Elevating low testosterone levels may improve features of the MetS and glycemic control. In a single blind, 52-week randomized clinical trial, the effects of supervised diet and exercise (D&E) with or without transdermal testosterone administration on components of the MetS in hypogonadal men with the MetS and newly diagnosed T2D were assessed. A total of 32 hypogonadal men (total testosterone <12.0 nmol/L) with newly diagnosed T2D and with the MetS as defined by the Adult Treatment Panel III and the International Diabetes Federation received supervised D&E, but 16 received it in combination with testosterone gel (50 mg) once daily (n = 16). No glucose-lowering agents were administered prior to or during the study period. Outcome measures were components of the MetS as defined by the Adult Treatment Panel III and the International Diabetes Federation. Serum testosterone, glycosylated hemoglobin (HbA_1c), fasting plasma glucose, high-density lipoprotein cholesterol, triglyceride concentrations, and the waist circumference improved in both treatment groups after 52 weeks of treatment. Addition of testosterone significantly further improved these measures compared with D&E alone. All D&E plus testosterone patients reached the HbA_1c goal of less than 7.0%; 87.5% of them reached an HbA_1c of less than 6.5%. Based on Adult Treatment Panel III guidelines, 81.3% of the patients randomized to D&E plus testosterone no longer matched the criteria of the MetS, whereas 31.3% of the D&E alone participants did. Additionally, testosterone treatment improved insulin sensitivity, adiponectin, and high-sensitivity C-reactive protein. Addition of testosterone to supervised D&E results in greater therapeutic improvements of glycemic control and reverses the MetS after 52 weeks of treatment in hypogonadal patients with the MetS and newly diagnosed T2D.

     Key words: Male hypogonadism, insulin resistance, HbA1c, lipids, blood pressure

This article has been cited by other articles:

				F. Saad, A. Aversa, A. M. Isidori, L. Zafalon, M. Zitzmann, and L. Gooren Onset of effects of testosterone treatment and time span until maximum effects are achieved Eur. J. Endocrinol., November 1, 2011; 165(5): 675 - 685. [Abstract] [Full Text] [PDF]

				P. Dandona and S. Dhindsa Update: Hypogonadotropic Hypogonadism in Type 2 Diabetes and Obesity J. Clin. Endocrinol. Metab., September 1, 2011; 96(9): 2643 - 2651. [Abstract] [Full Text] [PDF]

				M. Grossmann Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment J. Clin. Endocrinol. Metab., August 1, 2011; 96(8): 2341 - 2353. [Abstract] [Full Text] [PDF]

				C. Wang, G. Jackson, T. H. Jones, A. M. Matsumoto, A. Nehra, M. A. Perelman, R. S. Swerdloff, A. Traish, M. Zitzmann, and G. Cunningham Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes Diabetes Care, July 1, 2011; 34(7): 1669 - 1675. [Full Text] [PDF]

				T. H. Jones, S. Arver, H. M. Behre, J. Buvat, E. Meuleman, I. Moncada, A. M. Morales, M. Volterrani, A. Yellowlees, J. D. Howell, et al. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study) Diabetes Care, April 1, 2011; 34(4): 828 - 837. [Abstract] [Full Text] [PDF]

				J. S. Brand, I. van der Tweel, D. E. Grobbee, M. H. Emmelot-Vonk, and Y. T. van der Schouw Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies Int. J. Epidemiol., February 1, 2011; 40(1): 189 - 207. [Abstract] [Full Text] [PDF]

				G. R. Cunningham and S. M. Toma Why Is Androgen Replacement in Males Controversial? J. Clin. Endocrinol. Metab., January 1, 2011; 96(1): 38 - 52. [Abstract] [Full Text] [PDF]

				C. J. Malkin, P. J. Pugh, P. D. Morris, S. Asif, T. H. Jones, and K. S. Channer Low serum testosterone and increased mortality in men with coronary heart disease Heart, November 1, 2010; 96(22): 1821 - 1825. [Abstract] [Full Text] [PDF]